TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia

被引：25
|
作者：
Kikushige, Yoshikane [1 ]
Akashi, Koichi [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med, Dept Med & Biosyst Sci, Higashi Ku, Fukuoka 8128582, Japan
来源：
HEMATOPOIETIC STEM CELLS VIII | 2012年 / 1266卷
关键词：
leukemic stem cell; AML; TIM-3; ACUTE MYELOID-LEUKEMIA; PHAGOCYTOSIS; ACTIVATION; AUTOIMMUNE; HIERARCHY; RESPONSES; ANTIGEN; MARKER; IG;
D O I：
10.1111/j.1749-6632.2012.06550.x
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs inmost types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.
引用
收藏
页码：118 / 123
页数：6
相关论文
共 50 条
  • [1] TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
    Yoshikane Kikushige
    Toshihiro Miyamoto
    [J]. International Journal of Hematology, 2013, 98 : 627 - 633
  • [2] TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
    Kikushige, Yoshikane
    Miyamoto, Toshihiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (06) : 627 - 633
  • [3] TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
    Kikushige, Yoshikane
    Shima, Takahiro
    Takayanagi, Shin-ichiro
    Urata, Shingo
    Miyamoto, Toshihiro
    Iwasaki, Hiromi
    Takenaka, Katsuto
    Teshima, Takanori
    Tanaka, Toshiyuki
    Inagaki, Yoshimasa
    Akashi, Koichi
    [J]. CELL STEM CELL, 2010, 7 (06) : 708 - 717
  • [4] Leukemogenic Function of TIM-3, a Leukemia Stem Cell Marker, in Acute Myelogenous Leukemia and Myelodysplastic Syndromes
    Kikushige, Yoshikane
    Shima, Takahiro
    Yuda, Junichiro
    Miyamoto, Toshihiro
    Akashi, Koichi
    [J]. BLOOD, 2012, 120 (21)
  • [5] LEUKEMOGENIC FUNCTION OF TIM-3, A LEUKEMIA STEM CELL MARKER, IN ACUTE MYELOGENOUS LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
    Kikushige, Y.
    Yuda, J.
    Shima, T.
    Miyamoto, T.
    Akashi, K.
    [J]. HAEMATOLOGICA, 2013, 98 : 16 - 16
  • [6] TIM-3 Is a Promising Target to Eradicate Acute Myeloid Leukemia Stem Cells Sparing Normal Hematopoietic Stem Cells
    Miyamoto, Toshihiro
    Kikushige, Yoshikane
    Shima, Takahiro
    Akashi, Koichi
    [J]. BLOOD, 2011, 118 (21) : 257 - 257
  • [7] Expression and function of TIM-3, a potential therapeutic target in acute myeloid leukemia.
    Lee, Catherine Joy
    Kane, Lawrence Patrick
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Tim-3 as a leukemia stem cell specific marker expressing on bone marrow mononuclear cells is a factor for prognosis evaluation in patients with acute myelogenous leukemia
    Li, Xiang-Xin
    He, Xiao-Peng
    Ma, Chun-Hong
    Wang, Lu-Qun
    Li, Hao
    Li, Fang-Lin
    Hou, Ming
    Chen, Xue-Liang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 10979 - 10986
  • [9] TIM-3 as a therapeutic target in human inflammatory diseases
    Anderson, David E.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (08) : 1005 - 1009
  • [10] Analysis of Tim-3 as a therapeutic target in prostate cancer
    Piao, Yongrui
    Jin, Xuanshun
    [J]. TUMOR BIOLOGY, 2017, 39 (07) : 1 - 6
12345